GSK Upbeat On Alli In EU As Global Consumer Sales Show Healthy Gains
This article was originally published in The Tan Sheet
Executive Summary
Alli is off to the races in Europe, where it is generating high sales since launching in April, GlaxoSmithKline says
You may also be interested in...
Prestige Acquires 17 Glaxo OTC Brands, Enters Analgesics Market
Prestige Brands acquires GlaxoSmithKline’s BC and Goody’s analgesic brands as part of $660 million deal for 17 North American OTC lines, also including Beano gas treatment, FiberChoice supplement and Sominex sleep aid.
Prestige Acquires 17 Glaxo OTC Brands, Enters Analgesics Market
Prestige Brands acquires GlaxoSmithKline’s BC and Goody’s analgesic brands as part of $660 million deal for 17 North American OTC lines, also including Beano gas treatment, FiberChoice supplement and Sominex sleep aid.
Glaxo Adds Alli Warning Label In Europe
The European Union health authority recommended GlaxoSmithKline add a warning to alli nonprescription weight-loss drug, advising patients taking levothyroxine or antiepileptic drugs, or those with kidney disease, to consult a doctor before using